HAS3 (hyaluronan synthase 3) catalyzes the addition of GlcNAc or GlcUA monosaccharides to nascent hyaluronan polymers, serving as one of three isoenzymes responsible for hyaluronan (HA) synthesis 1. HA is a critical extracellular matrix component essential for tissue architecture, cell adhesion, migration, and differentiation 2. HAS3 expression is regulated at the promoter level through Sp1 binding sites and core promoter elements 2, with transcriptional regulation by inflammatory cytokines and growth factors 1. Beyond extracellular roles, intracellular HA produced by HAS3 participates in cell cycle regulation, cell motility, and autophagy 1. Disease relevance is substantial: elevated HAS3 expression correlates with metastasis and reduced survival in renal cell carcinoma, where HAS3 inhibition sensitizes tumors to sorafenib 3. In allergic airway inflammation, HAS3 upregulation promotes goblet cell hyperplasia through CD44-HA interactions 4. HAS3 also modulates airway hyper-reactivity in response to mechanical ventilation stress 5. Clinically, HAS3 represents a therapeutic target: 4-methylumbelliferone-mediated HAS3 inhibition suppresses disease-relevant HA synthesis in cancer and allergic inflammation models 34. Apigenin induces HAS3 expression to enhance skin barrier function 6, while age-related HAS3 downregulation contributes to ovarian fibrosis 7.